Gender differences in aspirin use among adults with coronary heart disease in the United States

Journal of General Internal Medicine

Volumn 22, Issue 1, 2007, Pages 55-61

  Opotowsky, Alexander R ^a,b   McWilliams, J Michael ^a   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aspirin; Coronary heart disease; Gender; Health; Insurance; Medical expenditure panel survey; Myocardial infarction; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; DATA ANALYSIS; DEMOGRAPHY; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIVATE HEALTH INSURANCE; RISK; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; UNITED STATES; AGE; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; HEALTH BEHAVIOR; HEALTH INSURANCE; RACE;

AGE FACTORS; AGED; ASPIRIN; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; FEMALE; HEALTH BEHAVIOR; HEALTH CARE SURVEYS; HUMANS; INSURANCE, HEALTH; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; UNITED STATES;

EID: 34248596694     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0116-5     Document Type: Article

References (55)

1. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81-06.
2. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136(2):157-60.
3. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293-304.
4. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-13.
5. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109(5):672-93.
6. Smith SC, Jr., Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38(5):1581-3.
7. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 1996;156(7):799-05.
8. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991;325(4):221-5.
9. Barakat K, Wilkinson P, Suliman A, Ranjadayalan K, Timmis A. Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. Am Heart J 2000;140(5):740-6.
10. Yarzebski J, Col N, Pagley P, Savageau J, Gore J, Goldberg R. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1996;131(1):43-50.
11. Rathore SS, Berger AK, Weinfurt KP, et al. Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. Circulation 2000;102(6):642-8.
12. Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol 1999;84(10):1145-50.
13. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996;124(3):292-8.
14. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003;55(6):604-8.
15. Jha AK, Perlin JB, Steinman MA, Peabody JW, Ayanian JZ. Quality of ambulatory care for women and men in the Veterans Affairs Health Care System. J Gen Intern Med 2005;20(8):762-5.
16. Persell SD, Maviglia SM, Bates DW, Ayanian JZ Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes. J Gen Intern Med 2005;20(2):123-30.
17. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113(2):203-12.
18. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000;101(10):1097-101.
19. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2(12):e353.
20. Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 1996;335(11):791-9.
21. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med 2001;134(3):173-81.
22. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999;159(6):561-7.
23. Agency for Healthcare Research and Quality Rockville M. Puf Data Files. June 2003. Available from: http://www.meps.ahrq.gov/Puf/DataResultsData.asp. Accessed 2004-2005.
24. Cohen JW, Monheit AC, Beauregard KM, et al. The Medical Expenditure Panel Survey: a national health information resource. Inquiry 1996;33(4):373-89.
25. Cohen SB. Design strategies and innovations in the medical expenditure panel survey. Med Care 2003;41(7 Suppl):III5-III12.
26. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005;28(7):1599-603.
27. Correa-de-Araujo R, Miller GE, Banthin JS, Trinh Y. Gender differences in drug use and expenditures in a privately insured population of older adults. J Womens Health (Larchmt) 2005;14(1):73-81.
28. Kass-Bartelmes BL, Altman BM, Taylor AK. Disparities and gender gaps in women's health, 1996. Rockville (MD): Agency for Healthcare Research and Quality; 2001. MEPS Chartbook No. 8;AHRQ Pub. No. 02-0003.
29. Johansson S, Bergstrand R, Ulvenstam G, et al. Sex differences in preinfarction characteristics and longterm survival among patients with myocardial infarction. Am J Epidemiol 1984;119(4):610-23.
30. Mahon NG, McKenna CJ, Codd MB, O'Rorke C, McCann HA, Sugrue DD. Gender differences in the management and outcome of acute myocardial infarction in unselected patients in the thrombolytic era. Am J Cardiol 2000;85(8):921-6.
31. Wenger NK. You've come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation 2004;109(5):558-60.
32. Ayanian JZ. Increased mortality among middle-aged women after myocardial infarction: searching for mechanisms and solutions. Ann Intern Med 2001;134(3):239-41.
33. Ayanian JZ, Landrum MB, Guadagnoli E, Gaccione P. Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction. N Engl J Med 2002;347(21):1678-86.
34. Mulrow C, Pignone M. An editorial update: should she take aspirin? Ann Intern Med 2005;142(11):942-3.
35. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38(11):1003-9.
36. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998;46(5):505-11.
37. Yamada T, Alpers D, Kaplowitz N, Loren L, Owyang C, Powel D. Textbook of gastroenterology. 4th ed: Lippincott Williams & Wilkins; 2003.
38. Center for Disease Control and Prevention. National Center for Health Statistics. Health Data for All Ages. Available from: http://www.cdc.gov/nchs/ healthdataforallages.htm. Accessed November 21st, 2005.
39. Sam C, Massaro JM, D'Agostino RB, Sr., et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94(7):947-51.
40. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321(3):129-35.
41. de Marco R, Locatelli F, Sunyer J, Burney P. Differences in incidence of reported asthma related to age in men and women. A retrospective analysis of the data of the European Respiratory Health Survey. Am J Respir Crit Care Med 2000;162(1):68-74.
42. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004;292(24):3017-23.
43. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347(13):969-974.
44. Hurlen M, Eikvar L, Seljeflot I, Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction A WARIS-II subgroup analysis. Thromb Res 2006;118(4): 433-38.
45. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995;5(4):270-77.
46. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. J Clin Epidemiol 1996;49(12):1407-17.
47. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57(10):1096-03.
48. Bowlin SJ, Morrill BD, Nafziger AN, Lewis C, Pearson TA. Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey. J Clin Epidemiol 1996;49(5):511-17.
49. Bowlin SJ, Morrill BD, Nafziger AN, Jenkins PL, Lewis C, Pearson TA. Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol 1993;46(6):561-71.
50. Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol 1998;147(10):969-77.
51. Martin LM, Leff M, Calonge N, Garrett C, Nelson DE. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med 2000;18(3):215-18.
52. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151(1):185-91.
53. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20(4):764-71.
54. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42(3):200-9.
55. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004;38(2):303-12.